J Korean Diabetes.  2017 Mar;18(1):20-25. 10.4093/jkd.2017.18.1.20.

Fungal Infection in Patients with Diabetes Mellitus

• Yun NR

• KMID: 2374763
• DOI: http://doi.org/10.4093/jkd.2017.18.1.20

Abstract

Diabetes mellitus is a major risk factor for fungal infections, and mortality increases when diagnosis and treatment of fungal infections are delayed in diabetic patients. Common fungal infections in diabetic patients are candidiasis, mucormycosis, and aspergillosis. These fungal infections show various clinical manifestations and are treated with various antifungal agents such as fluconazole, echinocandin, amphotericin B, and voriconazole. Early diagnosis and proper treatment are very important when fungal infection is suspected in diabetic patients.

Keyword

Aspergillosis; Candidiasis; Diabetes mellitus; Fungi; Mucormycosis

MeSH Terms

Amphotericin B
Antifungal Agents
Aspergillosis
Candidiasis
Diabetes Mellitus*
Diagnosis
Early Diagnosis
Fluconazole
Fungi
Humans
Mortality
Mucormycosis
Risk Factors
Voriconazole
Amphotericin B
Antifungal Agents
Fluconazole
Voriconazole

Reference

References

1. Singh G, Pitoyo CW, Aditianingsih D, Rumende CM. Risk factors for early invasive fungal disease in critically ill patients. Indian J Crit Care Med. 2016; 20:633–9.

2. Bartelink ML, Hoek L, Freriks JP, Rutten GE. Infections in patients with type 2 diabetes in general practice. Diabetes Res Clin Pract. 1998; 40:15–9.

3. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis. 2003; 3:772–85.

4. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016; 62:409–17.

5. Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016; 42:905–27.

6. Thomas L, Tracy CR. Treatment of fungal urinary tract infection. Urol Clin North Am. 2015; 42:473–83.

7. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005; 18:556–69.

8. Hong HL, Lee YM, Kim T, Lee JY, Chung YS, Kim MN, Kim SH, Choi SH, Kim YS, Woo JH, Lee SO. Risk factors for mortality in patients with invasive mucormycosis. Infect Chemother. 2013; 45:292–8.

9. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis. 2005; 40(Suppl 6):S401–8.

10. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009; 48:1743–51.

11. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev. 2005; 18:44–69.

12. Segal BH. Aspergillosis. N Engl J Med. 2009; 360:1870–84.

13. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004; 4:349–57.

14. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016; 63:e1–60.